Table 1 Sample characteristics and disease presenting features
From: The determinants and impact of diagnostic delay in lymphoma in a TB and HIV endemic setting
All (n = 163) | HIV - (n = 116) | HIV + (n = 47) | P-value | NHL (n = 122) | HL (n = 41) | P-value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sex | ||||||||||||
Male | 94 | 58% | 72 | 62% | 22 | 47% | 0.07 | 70 | 57% | 24 | 59% | |
Female | 69 | 42% | 44 | 38% | 25 | 53% | 52 | 43% | 17 | 41% | 0.90 | |
Age | ||||||||||||
Median (IQR) | 48 (33–59) | 54 (37–62) | 38 (30–47) | < 0.01 | 51 (38–61) | 35 (28–45) | < 0.01 | |||||
< 18 | 3 | 2% | 3 | 3% | 0 | 0% | 2 | 2% | 1 | 2% | ||
18–39 | 57 | 35% | 30 | 26% | 27 | 57% | 34 | 28% | 23 | 56% | ||
40–59 | 66 | 40% | 46 | 40% | 20 | 43% | 52 | 43% | 14 | 34% | ||
60–79 | 35 | 21% | 35 | 30% | 0 | 0% | 32 | 26% | 3 | 7% | ||
80 or older | 2 | 1% | 2 | 2% | 0 | 0% | 2 | 2% | 0 | 0% | ||
Race | ||||||||||||
Mixed ancestry | 81 | 50% | 77 | 66% | 4 | 9% | < 0.01 | 62 | 51% | 19 | 46% | |
Black | 59 | 36% | 18 | 16% | 41 | 87% | 40 | 33% | 19 | 46% | ||
White | 23 | 14% | 21 | 18% | 2 | 4% | 20 | 16% | 3 | 7% | 0.18 | |
Performance score | ||||||||||||
ECOG 0 | 19 | 12% | 14 | 12% | 5 | 11% | 0.97 | 11 | 9% | 8 | 20% | |
ECOG 1 | 74 | 45% | 54 | 47% | 20 | 43% | 53 | 43% | 21 | 51% | ||
ECOG 2 | 27 | 17% | 19 | 16% | 8 | 17% | 21 | 17% | 6 | 15% | ||
ECOG 3 | 32 | 20% | 22 | 19% | 10 | 21% | 27 | 22% | 5 | 12% | ||
ECOG 4 | 11 | 7% | 7 | 6% | 4 | 9% | 10 | 8% | 1 | 2% | 0.17 | |
Stage of disease at presentation | ||||||||||||
Stage 1 | 23 | 14% | 18 | 16% | 5 | 11% | 0.23 | 22 | 18% | 1 | 2% | 0.04 |
Stage 2 | 35 | 21% | 27 | 23% | 8 | 17% | 28 | 23% | 7 | 17% | ||
Stage 3 | 19 | 12% | 10 | 9% | 9 | 19% | 13 | 11% | 6 | 15% | ||
Stage 4 | 86 | 53% | 61 | 53% | 25 | 53% | 59 | 48% | 27 | 66% | ||
Bone marrow involved at diagnosis | 41 | 25% | 23 | 20% | 18 | 38% | 0.03 | 23 | 19% | 18 | 44% | < 0.01 |
Clinical presentation and investigations | ||||||||||||
Peripheral lymphadenopathy | 104 | 64% | 73 | 63% | 31 | 66% | 0.72 | 69 | 57% | 35 | 85% | < 0.01 |
B Symptoms | 96 | 59% | 66 | 57% | 30 | 64% | 0.42 | 66 | 54% | 30 | 73% | 0.03 |
Diagnosis made on bone marrow | 10 | 6% | 5 | 4% | 5 | 11% | 0.66 | 4 | 3% | 6 | 15% | 0.23 |
On TB therapy at diagnosis | 16 | 10% | 4 | 3% | 12 | 26% | < 0.01 | 5 | 4% | 11 | 27% | < 0.01 |
FNAC | ||||||||||||
Performed | 63 | 39% | 44 | 38% | 19 | 40% | 0.77 | 39 | 32% | 24 | 59% | < 0.01 |
Not performed | 100 | 61% | 72 | 62% | 28 | 60% | 83 | 68% | 17 | 41% | ||